drugset
drugset / Trial / NCT05469113

A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants

NCT05469113 ↗

Phase 1 Completed 16 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
Non-randomizedSequentialOpen-labelBasic science

Summary

The main purpose of this study is to assess the effect of selpercatinib on how fast repaglinide gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to 12 days.

Timeline

Start
2019-01-29
Primary completion
2019-03-05
Completion
2019-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Repaglinide Small molecule 0.5 mg Oral
Subject Selpercatinib Small molecule 160 mg Oral

Indications

No indication recorded.